430 Stock Overview
A clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Terns Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.04 |
| 52 Week High | US$7.70 |
| 52 Week Low | US$1.38 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 39.31% |
| 1 Year Change | -48.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 430 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -2.0% |
| 1Y | -48.2% | -15.6% | 6.9% |
Return vs Industry: 430 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 430 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 430 volatility | |
|---|---|
| 430 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 430's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 430's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 41 | Senthil Sundaram | www.ternspharma.com |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.
Terns Pharmaceuticals, Inc. Fundamentals Summary
| 430 fundamental statistics | |
|---|---|
| Market cap | €180.27m |
| Earnings (TTM) | -€56.90m |
| Revenue (TTM) | €968.20k |
186.2x
P/S Ratio-3.2x
P/E RatioIs 430 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 430 income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.00m |
| Other Expenses | US$59.77m |
| Earnings | -US$58.77m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -5,877.10% |
| Debt/Equity Ratio | 0% |
How did 430 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/13 14:25 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Terns Pharmaceuticals, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Corinne Johnson | Goldman Sachs |
| Corinne Johnson | Goldman Sachs |